Skip to main content

LCD L33623: Percutaneous Coronary Intervention

LCD L33623, Percutaneous Coronary Intervention, is the Local Coverage Determination that Wellpoint Federal applies to claims from 13 states (CT, DN, IL, MA, ME, MN, NH, NY and others), effective 2026-04-01 and first in force 2015-10-01. The policy text runs 713 words, and its billing and coding article A56823 lists 103 ICD-10-CM codes that support medical necessity for 22 procedure codes. No other contractor publishes a policy with this title.

QuickIntell editorial content · Legacy registry date · Review not verified

Data effective
Data currency: Medicare Coverage Database LCD export release of September 24, 2026 (effective September 20, 2026). Next CMS release: weekly (Thursdays) for the MCD.
Contractor
Wellpoint Federal
States and territories
13
CT DN IL MA ME MN NH NY QN RI UN VT WI
Revision effective
2026-04-01
Original effective
2015-10-01
Policy text
713 words
Covered ICD-10 codes (articles)
103

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33623
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACDN
13282Wellpoint FederalA and B and HHH MACUN
13292Wellpoint FederalA and B and HHH MACQN
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56823 (Billing and Coding: Percutaneous Coronary Intervention) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown.

A56823: Billing and Coding: Percutaneous Coronary Intervention (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
103
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
22
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56823
ICD-10-CMDescription (FY2027)
I20.0—
I20.81—
I20.89—
I20.9—
I21.01—
I21.02—
I21.09—
I21.11—
I21.19—
I21.21—
I21.29—
I21.3—
I21.4—
I21.9—
I21.A1—
I21.A9—
I21.B—
I22.0—
I22.1—
I22.2—
I22.8—
I22.9—
I24.0—
I24.81—

Procedure codes: 92920, 92924, 92928, 92930, 92933, 92937, 92941, 92943, 92973, 92978, 92979, 93571, 93572, C9600 (Percutaneous Transcatheter Placement Of Drug Eluting Intracoronary Stent(S), With Coronary Angioplasty When Performed; Single Major Coronary Artery Or Branch), C9601 (Percutaneous Transcatheter Placement Of Drug-Eluting Intracoronary Stent(S), With Coronary Angioplasty When Performed; Each Additional Branch Of A Major Coronary Artery (List Separately In Addition To Code For Primary Procedure)), C9602 (Percutaneous Transluminal Coronary Atherectomy, With Drug Eluting Intracoronary Stent, With Coronary Angioplasty When Performed; Single Major Coronary Artery Or Branch), C9603 (Percutaneous Transluminal Coronary Atherectomy, With Drug-Eluting Intracoronary Stent, With Coronary Angioplasty When Performed; Each Additional Branch Of A Major Coronary Artery (List Separately In Addition To Code For Primary Procedure)), C9604 (Percutaneous Transluminal Revascularization Of Or Through Coronary Artery Bypass Graft (Internal Mammary, Free Arterial, Venous), Any Combination Of Drug-Eluting Intracoronary Stent, Atherectomy And Angioplasty, Including Distal Protection When Performed; Single Vessel), C9605 (Percutaneous Transluminal Revascularization Of Or Through Coronary Artery Bypass Graft (Internal Mammary, Free Arterial, Venous), Any Combination Of Drug-Eluting Intracoronary Stent, Atherectomy And Angioplasty, Including Distal Protection When Performed; Each Additional Branch Subtended By The Bypass Graft (List Separately In Addition To Code For Primary Procedure)), C9606 (Percutaneous Transluminal Revascularization Of Acute Total/Subtotal Occlusion During Acute Myocardial Infarction, Coronary Artery Or Coronary Artery Bypass Graft, Any Combination Of Drug-Eluting Intracoronary Stent, Atherectomy And Angioplasty, Including Aspiration Thrombectomy When Performed, Single Vessel), C9607 (Percutaneous Transluminal Revascularization Of Chronic Total Occlusion, Coronary Artery, Coronary Artery Branch, Or Coronary Artery Bypass Graft, Any Combination Of Drug-Eluting Intracoronary Stent, Atherectomy And Angioplasty; Single Vessel), C9608 (Percutaneous Transluminal Revascularization Of Chronic Total Occlusion, Coronary Artery, Coronary Artery Branch, Or Coronary Artery Bypass Graft, Any Combination Of Drug-Eluting Intracoronary Stent, Atherectomy And Angioplasty; Each Additional Coronary Artery, Coronary Artery Branch, Or Bypass Graft (List Separately In Addition To Code For Primary Procedure)).

Coverage indications, limitations and medical necessity

Since Gruentzig’s 1979 report of coronary balloon angioplasty, percutaneous transluminal coronary interventions have substantively altered the management of patients with symptomatic arteriosclerotic heart disease. Balloon angioplasty rapidly expanded from single to multiple vessels and from simple to complex anatomic substrates. Transluminal interventions now encompass balloon dilation (PTCA), a variety of atherectomy devices, high pressure and biologic/polymer coated stents as well as transluminal thrombectomy. Additionally, intracoronary ultrasound is often employed to assess the efficacy of these interventions. In addition to medical therapy and coronary bypass surgery, percutaneous coronary intervention has emerged as a primary option for the management of patients with acute coronary syndromes and selected patients with chronic angina.

Indications:

Percutaneous coronary intervention (PCI) may be indicated in the management of :

• patients with acute coronary syndrome (eg acute myocardial infarction, unstable angina)

• patients with a history of significant obstructive atherosclerotic disease

• patients with restenosis of a coronary artery previously treated with intracoronary stent or other revascularization procedure

• patients with chronic angina

• patients with silent ischemia

Intracoronary ultrasound may be separately covered when needed to assess the extent of coronary stenosis if equivocal on angiography, or when needed to assess the patency and integrity of a coronary artery post-intervention. Alternatively, intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement may be performed to assess the degree of stenosis within a vessel.

Limitations:

A diagnostic cardiac catheterization to assess the nature of the lesion(s) prior to the intervention is a covered service. The diagnostic cardiac catheterization may be performed at any time prior to the PCI, including the same day as the PCI.

Performance of a diagnostic cardiac catheterization and interventional procedure on the same day is increasingly the standard of practice. While there may be reasons for delaying the interventional procedure (e.g., transfer from a community hospital to a tertiary center, excessive dye load, further treatment planning or evaluation of angiography, etc.), it is recommended that both procedures be performed during the same encounter when medically appropriate. Separation of these procedures for the purpose of circumventing the multiple surgery pricing, or for the convenience of physician or hospital scheduling, is considered an inappropriate practice and may subject the services to review and denial for medical necessity. The decision to stage these procedures is deferred to the judgment of the interventional cardiologist, and individualized only to the clinical needs of the patient. (e.g., dye load already received, need to correlate findings with other test results, etc). Reasons for delaying indicated intervention should be documented in the medical record. Unless there is a new clinical event or change in symptomatology, examination or other test results, a repeat diagnostic catheterization service within three months of a previous diagnostic catheterization, and prior to completion of the staged intervention is generally not reimbursable and is considered not to be reasonable and necessary.

Angiography during the procedure, used to monitor the course of the intervention, is considered part of the PCI and is not separately billable to Medicare. Diagnostic angiography may be separately payable in situations where no previous catheter-based coronary angiography study is available, or a previous study is no longer adequate due to changes in the patient’s condition.

The deployment of a device for distal embolic protection during an interventional procedure is considered part of the more complex procedure and is not separately billable.

Prophylactic insertion of a temporary transvenous pacemaker, repositioning or replacement of catheters and administration of medications during the procedure are included in the procedure and are not separately billable. Right heart catheterization and insertion of a Swan-Ganz catheter are not generally medically necessary for a PCI and will be denied, unless medically necessary when performed incident to a diagnostic catheterization prior to the intervention. Standby services of a surgeon or anesthesiologist are not covered services.

Intracoronary injections of drugs during diagnostic or therapeutic procedures are considered to be part of the procedure and are not separately reimbursable.

Percutaneous vascular closure devices (PVCD) may be used to facilitate closure of an arterial puncture site after angiography, cardiac catheterization and interventional cardiology procedures in addition to or in place of manual compression, use of a mechanical clamp or a sandbag, or a combination of these methods. These services are inherent to the invasive procedure and are not separately payable.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2016-12-21
MCD version
26
Derived from
L28395

The contractor lists one National Coverage Determination as related: NCD 20.7 Percutaneous Transluminal Angioplasty (PTA). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line, and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

Frequently asked questions

What does LCD L33623 cover?

Since Gruentzig’s 1979 report of coronary balloon angioplasty, percutaneous transluminal coronary interventions have substantively altered the management of patients with symptomatic arteriosclerotic heart disease. Balloon angioplasty rapidly expanded from single to multiple vessels and from simple to complex anatomic substrates. Transluminal interventions now encompass balloon dilation (PTCA), a variety of… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database export of September 24, 2026.

Which states does LCD L33623 apply to?

Wellpoint Federal applies it to Medicare claims in CT, DN, IL, MA, ME, MN, NH, NY, QN, RI, UN, VT, WI. A Local Coverage Determination binds only the contractor that wrote it; the same service in another jurisdiction is judged under that contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33623?

The companion billing and coding article A56823 lists 103 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page and the complete list is in the article on cms.gov.

How do I appeal a denial under LCD L33623?

The remittance carries claim adjustment reason code 50 with remark code N115, naming the LCD. Compare the documented indication with the policy's covered indications and the article's diagnosis list, then file a redetermination within 120 days with the record attached; if the service genuinely falls outside the policy, the patient can be billed only when a valid Advance Beneficiary Notice was obtained before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.